FDA Making A Generic Case For Continuous Manufacturing
Executive Summary
The industry that makes the vast majority of drugs has yet to embrace the new production approach, but FDA hopes that platform standardization will make it more compelling.
You may also be interested in...
New CDER Lab Will Help Push Advanced Manufacturing Adoption
US FDA plans to open a manufacturing research lab near its White Oak headquarters in 2021 to facilitate evaluation of novel manufacturing technology.
ANDA Amendments Cannot Get Mid-Review Communications Like Full Applications - FDA
Generic industry officials ask that information requests and discipline review letters be issued during ANDA amendment assessments, but the US agency says they are not allowed in GDUFA II.
ANDA Amendments Cannot Get Mid-Review Communications Like Full Applications - FDA
Generic industry officials ask that information requests and discipline review letters be issued during ANDA amendment assessments, but the US agency says they are not allowed in GDUFA II.